Target intelligence / Profile preview

Cyclic nucleotide-gated channel subunit beta 3 (CNGB3)

Target
CNGB3
Molecular classification
Ion channel, Cyclic nucleotide-gated channel, Member of cyclic nucleotide-regulated channels (CNG)
01

Overview

Cyclic nucleotide-gated channel subunit beta 3 (CNGB3) is a regulatory subunit of cone CNG channels, which form heterotetramers composed typically of three CNGA3 subunits and one CNGB3 subunit in humans. These channels transduce chemical signals induced by light into electrical signals crucial for color vision. CNGB3 contributes to unique structural and functional properties of cone channels, influencing ion selectivity and channel gating. Mutations in CNGB3 are a major genetic cause of achromatopsia, a congenital inability to perceive color, and related degenerative retinal diseases. CNGB3 does not form functional channels on its own but modulates channel properties when assembled with CNGA3.

Other names
CNGB3ACHM1Cyclic nucleotide-gated channel beta 3Cyclic nucleotide gated channel subunit beta 3
02

Mechanism of action

Drugs or molecules that modulate CNG channels typically alter channel gating by binding or interfering with the cyclic nucleotide-binding domain, affecting ion flow and photoreceptor response.

03

Biological functions

Electrical signal transduction in cone photoreceptors (critical for vision)Ion conductance (cations, especially in response to cyclic nucleotides such as cGMP and cAMP)Ligand-gated channel activity
04

Disease associations

Neurodegenerative disease (notably visual disorders)Achromatopsia (ACHM)Cone dystrophyProgressive macular degenerationMacular dystrophy
05

Safety considerations

Loss-of-function or gain-of-function mutations in CNGB3 can lead to inherited blindness or visual impairmenttherapeutic challenges involve restoring correct channel function in affected photoreceptors
06

Interacting drugs

cGMP-analogues

1 more in the full profile.

07

Biomarkers

Mutations in the *CNGB3* gene (such as R403Q) serve as biomarkers for diagnoses and patient stratification in achromatopsia and related cone disorders

Beyond the preview

Go deeper on Cyclic nucleotide-gated channel subunit beta 3 (CNGB3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic nucleotide-gated channel subunit beta 3 (CNGB3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call